Matinas BioPharma Holdings Inc., a Bedminster-based biopharmaceutical company, announced it has appointed Dominick DiPaolo as its new senior vice president of quality and regulatory compliance.Matinas ...
Evelyn D’An has been appointed as an independent director and Chair of the Audit Committee, bringing extensive corporate governance and financial oversight experience to Matinas BioPharma's Board of ...
Maxim downgraded Matinas BioPharma (MTNB) to Hold from Buy. The company announced that partnering negotiations for its lead asset MAT2203 – oral amphotericin – as part of the previously disclosed ...
Matinas BioPharma Holdings, a clinical stage biopharmaceutical company, on Thursday announced they signed an agreement with an undisclosed top global pharmaceutical company aimed to evaluate ...
Matinas BioPharma Hldgs (MTNB) is scheduled to report earnings on November 12, 2025. The last reported earnings were for reported on August 14, 2025 for Q2. The Actual Revenue was $0K, which hit the ...
BEDMINSTER, N.J., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Matinas BioPharma (MTNB) Holdings, Inc. (NYSE American: MTNB), a clinical-stage biopharmaceutical company focused on delivering groundbreaking ...
111 Equity Group and its principal filed a Schedule 13D with the SEC to disclose that 111 Equity and its principal have collectively accumulated a 5.17% stock ownership stake in Matinas Biopharma ...
Matinas BioPharma is a biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (LNC) platform delivery technology. Matinas’ lead LNC-based therapy is ...
Matinas BioPharma Holdings, Inc. (AMEX: MTNB) Q4 2022 Earnings Call Transcript March 15, 2023 Operator: Greetings and welcome to the Matinas BioPharma 2022 Fourth Quarter and Full Year Conference Call ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results